You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 151 No. 12, DECEMBER 1991 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL INVESTIGATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Thrush Can Be Prevented in Patients With Acquired Immunodeficiency Syndrome and the Acquired Immunodeficiency Syndrome—Related Complex

Randomized, Double-blind, Placebo-Controlled study of 100-mg Oral Fluconazole Daily

David A. Stevens, MD; S. Ira Greene, MD; Onnie S. Lang, RN

Arch Intern Med. 1991;151(12):2458-2464.


Abstract

Recurrent oropharyngeal candidiasis is common in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome—related complex. It causes local pain and discomfort, loss of taste, and aversion to food and may lead to secondary complications. We examined, in a double-blind study, whether recurrent thrush could be prevented by prophylaxis. Twenty-five patients with one to four previous thrush episodes who had no thrush at the outset of the study were randomized to receive 100 mg of fluconazole or placebo daily for 12 weeks. If thrush occurred, prophylaxis was stopped and patients were treated conventionally, after which prophylaxis was resumed. After the randomized study, some patients were given continuous fluconazole (open phase). In the randomized study, thrush occurred in eight of 13 placebo-treated patients and none of 12 fluconazole-treated patients. possible side effects were not different between the groups. Dermatophytosis and onychomycosis and cryptococcuria also improved in the fluconazole-treated patients, and fungal colonization was significantly decreased. One episode of thrush occurred in the open phase in an intermittently compliant patient (group total, 71.5 patient-months of fluconazole treatment); in contrast, the 25 patients also had had two episodes of Candida esophagitis, three of cryptococcosis, and 13 of dermatophytosis before entry. Subsequent to entry in the randomized trial, in 92.3 patientmonths without fluconazole, there were 35 episodes of thrush, one of esophagitis, one of cryptococcemia, and one of dermatophytosis, and preexisting dermatophytosis and onychomycosis were unchanged or worsened. Individual patients observed with and without fluconazole treatment also showed its efficacy. In conclusion, thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome— related complex with negligible toxic effects. Larger trials to confirm prevention of all mycoses with prophylaxis should be considered.

(Arch Intern Med. 1991;151:2458-2464)



Author Affiliations

From the AIDS Program (Drs Stevens and Greene and Ms Lang) and Divisions of Infectious Diseases (Dr Stevens) and Dermatology (Dr Greene), Department of Medicine, Santa Clara Valley Medical Center, San Jose, Calif; California Institute for Medical Research, San Jose (Dr Stevens); and Stanford (Calif) University Medical School (Drs Stevens and Greene).


Footnotes

Accepted for publication May 29, 1991.

Presented in part at the Sixth International Conference on AIDS, San Francisco, Calif, June 1990.

Reprint requests to Division of Infectious Diseases, Department of Medicine, Santa Clara Valley Medical Center, 751 S Bascom Ave, San Jose, CA 95128 (Dr Stevens).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?
Charlier et al.
J Antimicrob Chemother 2006;57:384-410.
ABSTRACT | FULL TEXT  

Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial
Pagani et al.
J Antimicrob Chemother 2002;50:231-240.
ABSTRACT | FULL TEXT  

Fluconazole as Prophylaxis Against Fungal Infection in Patients With Advanced HIV Infection
Manfredi et al.
Arch Intern Med 1997;157:64-69.
ABSTRACT  

A Randomized Trial Comparing Fluconazole with Clotrimazole Troches for the Prevention of Fungal Infections in Patients with Advanced Human Immunodeficiency Virus Infection
Powderly et al.
NEJM 1995;332:700-705.
ABSTRACT | FULL TEXT  

Preventive Health Care for Adults With HIV Infection
Jewett and Hecht
JAMA 1993;269:1144-1153.
ABSTRACT  

PREVENTION OF ORAL THRUSH WITH FLUCONAZOLE
JWatch General 1992;1992:6-6.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.